3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
2
Phase 2
2
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
6
Pain
3
Pain, Postoperative
2
Agnosia
2
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Postoperative Complications
1
Ovarian Cysts
1
Neoplasms
1
Malignant Neoplasms of Male Genital Organs
1
Intraoperative Complications
1
Goiter
1
Colorectal Neoplasms
1
Chronic Pain
1
Carcinoma, Renal Cell
1
Advanced Ovarian Cancer
1
Abdominal Neoplasms
1
Interventions
Paclitaxel
20
Gemcitabine
16
Dexamethasone
16
Bevacizumab
16
Docetaxel
15
Oxaliplatin
14
Cyclophosphamide
13
Carboplatin
12
Capecitabine
12
Sorafenib
11
Fluorouracil
11
Leucovorin
10
Cisplatin
10
pembrolizumab
9
Pemetrexed
9
Epoetin Alfa
9
venetoclax
8
Prednisone
8
Fentanyl
8
Drug Therapy
8
Doxorubicin
8
atezolizumab
7
Rivaroxaban
7
Rituximab
7
Darbepoetin alfa
7
Anastrozole
7
Panitumumab
6
Ondansetron
6
Morphine
6
Irinotecan
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Neoplasms
×
Ropivacaine
×
Clear all
NCT02256228
2019-01-15
IPLA
Göteborg University
Phase 3
Completed
40 enrolled